Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Tuberculosis, HIV, and viral hepatitis diagnostics in eastern Europe and central Asia: high time for integrated and people-centred services.

Dara M, Ehsani S, Mozalevskis A, Vovc E, Simões D, Avellon Calvo A, Casabona I Barbarà J, Chokoshvili O, Felker I, Hoffner S, Kalmambetova G, Noroc E, Shubladze N, Skrahina A, Tahirli R, Tsertsvadze T, Drobniewski F.

Lancet Infect Dis. 2019 Nov 15. pii: S1473-3099(19)30524-9. doi: 10.1016/S1473-3099(19)30524-9. [Epub ahead of print] Review.

PMID:
31740252
2.

Extensive global movement of multidrug-resistantM. tuberculosis strains revealed by whole-genome analysis.

Cohen KA, Manson AL, Abeel T, Desjardins CA, Chapman SB, Hoffner S, Birren BW, Earl AM.

Thorax. 2019 Sep;74(9):882-889. doi: 10.1136/thoraxjnl-2018-211616. Epub 2019 May 2.

3.

Direct drug susceptibility testing of Mycobacterium tuberculosis using the proportional method: A multicenter study.

Amini S, Hoffner S, Allahyar Torkaman MR, Hamzehloo G, Nasiri MJ, Salehi M, Sami Kashkooli G, Shahraki MS, Mohsenpoor M, Soleimanpour S, Mir R.

J Glob Antimicrob Resist. 2019 Jun;17:242-244. doi: 10.1016/j.jgar.2018.12.022. Epub 2019 Jan 7.

PMID:
30630107
4.

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, McNerney R, Cirillo DM, Schito M, Rodwell TC, Posey J.

Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1.

5.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

6.

Molecular characterization of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Khartoum, Sudan.

Elegail A, Ibrahim Mohamed NY, Mohamed Nour EO, Hoffner S, Haile M.

Int J Mycobacteriol. 2018 Jul-Sep;7(3):236-241. doi: 10.4103/ijmy.ijmy_82_18.

7.

Multi-center evaluation of GenoType MTBDRsl line probe assay for rapid detection of pre-XDR and XDR Mycobacterium tuberculosis in China.

Gao Y, Zhang Z, Deng J, Mansjö M, Ning Z, Li Y, Li X, Hu Y, Hoffner S, Xu B.

J Infect. 2018 Oct;77(4):328-334. doi: 10.1016/j.jinf.2018.06.014. Epub 2018 Jun 30.

PMID:
29969597
8.

The Epidemiological Significance and Temporal Stability of Mycobacterial Interspersed Repetitive Units-Variable Number of Tandem Repeats-Based Method Applied to Mycobacterium tuberculosis in China.

Li Y, Hu Y, Mansjö M, Zhao Q, Jiang W, Ghebremichael S, Hoffner S, Xu B.

Int J Environ Res Public Health. 2018 Apr 17;15(4). pii: E782. doi: 10.3390/ijerph15040782.

9.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

10.

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.

Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC.

Eur Respir J. 2017 Dec 28;50(6). pii: 1701354. doi: 10.1183/13993003.01354-2017. Print 2017 Dec.

11.

Detection of Mycobacterium tuberculosis pncA Mutations by the Nipro Genoscholar PZA-TB II Assay Compared to Conventional Sequencing.

Willby MJ, Wijkander M, Havumaki J, Johnson K, Werngren J, Hoffner S, Denkinger CM, Posey JE.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01871-17. doi: 10.1128/AAC.01871-17. Print 2018 Jan.

12.

Mycobacterium tuberculosis of the Beijing Genotype in Iran and the World Health Organization Eastern Mediterranean Region: A Meta-Analysis.

Hoffner S, Sahebi L, Ansarin K, Sabour S, Mohajeri P.

Microb Drug Resist. 2018 Jul/Aug;24(6):693-698. doi: 10.1089/mdr.2017.0160. Epub 2017 Oct 23.

PMID:
29058526
13.

Drug-resistant Mycobacterium tuberculosis: Epidemiology and role of morphological alterations.

Velayati AA, Farnia P, Hoffner S.

J Glob Antimicrob Resist. 2018 Mar;12:192-196. doi: 10.1016/j.jgar.2017.10.006. Epub 2017 Oct 16. Review.

PMID:
29042338
14.

Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015.

Mansjo M, Werngren J, Hoffner S.

Int J Mycobacteriol. 2017 Apr-Jun;6(2):156-161. doi: 10.4103/ijmy.ijmy_23_17.

15.

Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.

Anthony RM, Cynamon M, Hoffner S, Werngren J, den Hertog AL, van Soolingen D.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00258-17. doi: 10.1128/AAC.00258-17. Print 2017 Jun. No abstract available.

16.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.

Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J; TBResist Global Genome Consortium, Chapman SB, Cho SN, Gabrielian A, Gomez J, Jodals AM, Joloba M, Jureen P, Lee JS, Malinga L, Maiga M, Nordenberg D, Noroc E, Romancenco E, Salazar A, Ssengooba W, Velayati AA, Winglee K, Zalutskaya A, Via LE, Cassell GH, Dorman SE, Ellner J, Farnia P, Galagan JE, Rosenthal A, Crudu V, Homorodean D, Hsueh PR, Narayanan S, Pym AS, Skrahina A, Swaminathan S, Van der Walt M, Alland D, Bishai WR, Cohen T, Hoffner S, Birren BW, Earl AM.

Nat Genet. 2017 Mar;49(3):395-402. doi: 10.1038/ng.3767. Epub 2017 Jan 16.

17.

Multidrug-resistant tuberculosis: The problem and some priorities in controlling it.

Hoffner S.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S59. doi: 10.1016/j.ijmyco.2016.10.031. Epub 2016 Nov 22.

18.

Impact of genotypic and phenotypic resistance to second-line anti-tuberculosis drugs on treatment outcomes in multidrug-resistant tuberculosis in China.

Hu Y, Zheng X, Ning Z, Li Q, Zhang Z, Hoffner S.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S34-S35. doi: 10.1016/j.ijmyco.2016.11.007. Epub 2016 Nov 22.

19.

Beijing strains of Mycobacterium tuberculosis in smear-positive tuberculosis patients in North-West and West of Iran.

Sahebi L, Ansarin K, Hoffner S, Mohajeri P, Mohammadi A.

Adv Biomed Res. 2016 Nov 28;5:181. doi: 10.4103/2277-9175.190982. eCollection 2016.

20.

Whole-Genome Sequencing of Mycobacterium tuberculosis Provides Insight into the Evolution and Genetic Composition of Drug-Resistant Tuberculosis in Belarus.

Wollenberg KR, Desjardins CA, Zalutskaya A, Slodovnikova V, Oler AJ, Quiñones M, Abeel T, Chapman SB, Tartakovsky M, Gabrielian A, Hoffner S, Skrahin A, Birren BW, Rosenthal A, Skrahina A, Earl AM.

J Clin Microbiol. 2017 Feb;55(2):457-469. doi: 10.1128/JCM.02116-16. Epub 2016 Nov 30.

21.

Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages.

Stucki D, Brites D, Jeljeli L, Coscolla M, Liu Q, Trauner A, Fenner L, Rutaihwa L, Borrell S, Luo T, Gao Q, Kato-Maeda M, Ballif M, Egger M, Macedo R, Mardassi H, Moreno M, Tudo Vilanova G, Fyfe J, Globan M, Thomas J, Jamieson F, Guthrie JL, Asante-Poku A, Yeboah-Manu D, Wampande E, Ssengooba W, Joloba M, Henry Boom W, Basu I, Bower J, Saraiva M, Vaconcellos SEG, Suffys P, Koch A, Wilkinson R, Gail-Bekker L, Malla B, Ley SD, Beck HP, de Jong BC, Toit K, Sanchez-Padilla E, Bonnet M, Gil-Brusola A, Frank M, Penlap Beng VN, Eisenach K, Alani I, Wangui Ndung'u P, Revathi G, Gehre F, Akter S, Ntoumi F, Stewart-Isherwood L, Ntinginya NE, Rachow A, Hoelscher M, Cirillo DM, Skenders G, Hoffner S, Bakonyte D, Stakenas P, Diel R, Crudu V, Moldovan O, Al-Hajoj S, Otero L, Barletta F, Jane Carter E, Diero L, Supply P, Comas I, Niemann S, Gagneux S.

Nat Genet. 2016 Dec;48(12):1535-1543. doi: 10.1038/ng.3704. Epub 2016 Oct 31.

22.
23.

A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing.

Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A.

J Clin Microbiol. 2016 Dec;54(12):2956-2962. Epub 2016 Sep 21.

24.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

25.

Outcomes of a clinical diagnostic algorithm for management of ambulatory smear and Xpert MTB/Rif negative HIV infected patients with presumptive pulmonary TB in Uganda: a prospective study.

Walusimbi S, Semitala F, Bwanga F, Haile M, De Costa A, Davis L, Joloba M, Hoffner S, Kamya M.

Pan Afr Med J. 2016 Mar 31;23:154. doi: 10.11604/pamj.2016.23.154.7995. eCollection 2016.

26.

Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.

Li D, Hu Y, Werngren J, Mansjö M, Zheng X, Drobniewski F, Hoffner S, Xu B.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5159-66. doi: 10.1128/AAC.02687-15. Print 2016 Sep.

27.

Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.

Zheng X, Zheng R, Hu Y, Werngren J, Forsman LD, Mansjö M, Xu B, Hoffner S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4786-92. doi: 10.1128/AAC.03008-15. Print 2016 Aug.

28.

Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis.

Gustafsson TN, Osman H, Werngren J, Hoffner S, Engman L, Holmgren A.

Biochim Biophys Acta. 2016 Jun;1860(6):1265-71. doi: 10.1016/j.bbagen.2016.03.013. Epub 2016 Mar 10.

PMID:
26971857
29.

Populations of latent Mycobacterium tuberculosis lack a cell wall: Isolation, visualization, and whole-genome characterization.

Velayati AA, Abeel T, Shea T, Konstantinovich Zhavnerko G, Birren B, Cassell GH, Earl AM, Hoffner S, Farnia P.

Int J Mycobacteriol. 2016 Mar;5(1):66-73. doi: 10.1016/j.ijmyco.2015.12.001. Epub 2015 Dec 28.

30.

Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment.

Hu Y, Zhao Q, Werngren J, Hoffner S, Diwan VK, Xu B.

BMC Infect Dis. 2016 Jan 7;16:4. doi: 10.1186/s12879-015-1331-z.

31.

Molecular Epidemiology of Mycobacterium Tuberculosis Strains in the North-West and West of Iran.

Sahebi L, Ansarin K, Hoffner S, Farajnia S, Seyyedi M, Khalili M, Monfaredan A.

Ann Med Health Sci Res. 2015 Sep-Oct;5(5):334-9. doi: 10.4103/2141-9248.165249.

32.

Beijing clades of Mycobacterium tuberculosis are associated with differential survival in HIV-negative Russian patients.

Balabanova Y, Nikolayevskyy V, Ignatyeva O, Kontsevaya I, Mironova S, Kovalyov A, Kritsky A, Rodionova Y, Fedorin I, Casali N, Hooper R, Horstmann RD, Nejentsev S, Hoffner S, Nuernberg P, Drobniewski F.

Infect Genet Evol. 2015 Dec;36:517-523. doi: 10.1016/j.meegid.2015.08.028. Epub 2015 Aug 28.

PMID:
26319998
33.

Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs.

Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M.

Geneva: World Health Organization; 2008.

34.

Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study.

Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjö M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM.

J Clin Microbiol. 2015 Sep;53(9):2961-9. doi: 10.1128/JCM.01257-15. Epub 2015 Jul 15.

35.

Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage.

Merker M, Blin C, Mona S, Duforet-Frebourg N, Lecher S, Willery E, Blum MG, Rüsch-Gerdes S, Mokrousov I, Aleksic E, Allix-Béguec C, Antierens A, Augustynowicz-Kopeć E, Ballif M, Barletta F, Beck HP, Barry CE 3rd, Bonnet M, Borroni E, Campos-Herrero I, Cirillo D, Cox H, Crowe S, Crudu V, Diel R, Drobniewski F, Fauville-Dufaux M, Gagneux S, Ghebremichael S, Hanekom M, Hoffner S, Jiao WW, Kalon S, Kohl TA, Kontsevaya I, Lillebæk T, Maeda S, Nikolayevskyy V, Rasmussen M, Rastogi N, Samper S, Sanchez-Padilla E, Savic B, Shamputa IC, Shen A, Sng LH, Stakenas P, Toit K, Varaine F, Vukovic D, Wahl C, Warren R, Supply P, Niemann S, Wirth T.

Nat Genet. 2015 Mar;47(3):242-9. doi: 10.1038/ng.3195. Epub 2015 Jan 19.

PMID:
25599400
36.

Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.

Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, Matthys V, Hoffner S, Richter E, Perez Del Molino ML, Cirillo DM, van Soolingen D, Böttger EC.

J Antimicrob Chemother. 2015 Mar;70(3):686-96. doi: 10.1093/jac/dku438. Epub 2014 Nov 11.

37.

Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.

Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopeć E, Degano M, Ambrosi A, Hoffner S, Mansjö M, Werngren J, Rüsch-Gerdes S, Niemann S, Cirillo DM.

MBio. 2014 Oct 21;5(5):e01819-14. doi: 10.1128/mBio.01819-14.

38.

Evaluation of a microcolony growth monitoring method for the rapid determination of ethambutol resistance in Mycobacterium tuberculosis.

den Hertog AL, Menting S, Smienk ET, Werngren J, Hoffner S, Anthony RM.

BMC Infect Dis. 2014 Jul 10;14:380. doi: 10.1186/1471-2334-14-380.

39.

Evaluation of a biphasic media assay for pyrazinamide drug susceptibility testing of Mycobacterium tuberculosis.

Gonzalo X, Drobniewski F, Hoffner S, Werngren J.

J Antimicrob Chemother. 2014 Nov;69(11):3001-5. doi: 10.1093/jac/dku230. Epub 2014 Jun 23.

PMID:
24962032
40.

Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.

Hameed P S, Patil V, Solapure S, Sharma U, Madhavapeddi P, Raichurkar A, Chinnapattu M, Manjrekar P, Shanbhag G, Puttur J, Shinde V, Menasinakai S, Rudrapatana S, Achar V, Awasthy D, Nandishaiah R, Humnabadkar V, Ghosh A, Narayan C, Ramya VK, Kaur P, Sharma S, Werngren J, Hoffner S, Panduga V, Kumar CN, Reddy J, Kumar K N M, Ganguly S, Bharath S, Bheemarao U, Mukherjee K, Arora U, Gaonkar S, Coulson M, Waterson D, Sambandamurthy VK, de Sousa SM.

J Med Chem. 2014 Jun 12;57(11):4889-905. doi: 10.1021/jm500432n. Epub 2014 May 23.

PMID:
24809953
41.

In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.

Werngren J, Wijkander M, Perskvist N, Balasubramanian V, Sambandamurthy VK, Rodrigues C, Hoffner S.

Antimicrob Agents Chemother. 2014 Jul;58(7):4222-3. doi: 10.1128/AAC.02718-14. Epub 2014 Apr 28.

42.

Comparison between RFLP and MIRU-VNTR genotyping of Mycobacterium tuberculosis strains isolated in Stockholm 2009 to 2011.

Jonsson J, Hoffner S, Berggren I, Bruchfeld J, Ghebremichael S, Pennhag A, Groenheit R.

PLoS One. 2014 Apr 14;9(4):e95159. doi: 10.1371/journal.pone.0095159. eCollection 2014.

43.

Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data.

Zignol M, Dara M, Dean AS, Falzon D, Dadu A, Kremer K, Hoffmann H, Hoffner S, Floyd K.

Drug Resist Updat. 2013 Dec;16(6):108-15. doi: 10.1016/j.drup.2014.02.003. Epub 2014 Feb 28. Review.

44.

Multidrug-resistant Myobacterium tuberculosis caused by the Beijing genotype and a specific T1 genotype clone (SIT No. 266) is widely transmitted in Minsk.

Zalutskaya A, Wijkander M, Jureen P, Skrahina A, Hoffner S.

Int J Mycobacteriol. 2013 Dec;2(4):194-8. doi: 10.1016/j.ijmyco.2013.08.001. Epub 2013 Sep 6.

45.

The role of drug susceptibility testing in M/XDR-TB. Too little and too late - Are we doing the right things?

Hoffner SE.

Int J Mycobacteriol. 2013 Dec;2(4):191-3. doi: 10.1016/j.ijmyco.2013.10.003. Epub 2013 Nov 1. No abstract available.

46.

High prevelance of rifampin-monoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients.

Velayati AA, Farnia P, Mozafari M, Sheikholeslami MF, Karahrudi MA, Tabarsi P, Hoffner S.

Am J Trop Med Hyg. 2014 Jan;90(1):99-105. doi: 10.4269/ajtmh.13-0057. Epub 2013 Nov 4.

47.

Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis.

Walusimbi S, Bwanga F, De Costa A, Haile M, Joloba M, Hoffner S.

BMC Infect Dis. 2013 Oct 30;13:507. doi: 10.1186/1471-2334-13-507.

48.

First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries.

Hillemann D, Hoffner S, Cirillo D, Drobniewski F, Richter E, Rüsch-Gerdes S; Baltic-Nordic TB- Laboratory Network; TB PAN-NET; ECDC ERLN-TB Networks.

PLoS One. 2013 Oct 11;8(10):e76765. doi: 10.1371/journal.pone.0076765. eCollection 2013.

49.

Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis.

P SH, Solapure S, Mukherjee K, Nandi V, Waterson D, Shandil R, Balganesh M, Sambandamurthy VK, Raichurkar AK, Deshpande A, Ghosh A, Awasthy D, Shanbhag G, Sheikh G, McMiken H, Puttur J, Reddy J, Werngren J, Read J, Kumar M, R M, Chinnapattu M, Madhavapeddi P, Manjrekar P, Basu R, Gaonkar S, Sharma S, Hoffner S, Humnabadkar V, Subbulakshmi V, Panduga V.

Antimicrob Agents Chemother. 2014;58(1):61-70. doi: 10.1128/AAC.01751-13. Epub 2013 Oct 14. Erratum in: Antimicrob Agents Chemother. 2014 Aug;58(8):4993-4.

50.

Proficiency of drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide: the Swedish experience.

Hoffner S, Angeby K, Sturegård E, Jönsson B, Johansson A, Sellin M, Werngren J.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1486-90. doi: 10.5588/ijtld.13.0195.

PMID:
24125455

Supplemental Content

Loading ...
Support Center